Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation

被引：49

作者：

Jia, Hejin ^{[1
]}

Wang, Zhenguang ^{[1
]}

Wang, Yao ^{[1
]}

Liu, Yang ^{[2
]}

Dai, Hanren ^{[1
]}

Tong, Chuan ^{[1
]}

Guo, Yelei ^{[1
]}

Guo, Bo ^{[2
]}

Ti, Dongdong ^{[1
]}

Han, Xiao ^{[1
]}

Yang, Qingming ^{[1
]}

Wu, Zhiqiang ^{[1
]}

Han, Weidong ^{[1
]}

机构：

[1] Chinese Peoples Liberat Army Gen Hosp, Biotherapeut Dept, Mol & Immunol Dept, 28 Fuxing Rd, Beijing 100853, Peoples R China

[2] Chinese Peoples Liberat Army Gen Hosp, Dept Geriatr Hematol, 28 Fuxing Rd, Beijing 100853, Peoples R China

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2019年 / 12卷 / 1期

基金：

中国国家自然科学基金;

关键词：

Chimeric antigen receptor; CAR-T; Bispecific CAR-T; GVHD; Haploidentical CAR-T; VERSUS-HOST-DISEASE; PHASE-I; GRAFT; INFUSION; LEUKEMIA; CHILDREN;

D O I：

10.1186/s13045-019-0741-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundChimeric antigen receptor T (CAR-T) cell therapy simultaneously against CD19 and CD22 is an attractive strategy to address the antigen escape relapse after CD19-directed CAR-T cell therapies. However, the potential of optimizing the durability of remission by this approach in patients with B cell acute lymphoblastic leukemia (B-ALL) remains a critical unanswered question so far.Case presentationWe treated an adult patient with relapsed and refractory B-ALL after haploidentical hematopoietic stem cell transplantation (HSCT) by administering haploidentical CAR-T cells targeting both CD19 and CD22 following preparative lymphodepleting chemotherapy. This patient has remained in minimal residual disease-negative remission for more than 14months and has been tapered off graft versus host disease prophylaxis.ConclusionsCAR simultaneously targeting CD19 and CD22 has the potential of inducing long-term remission in patients with B-ALL.

引用

页数：9

共 28 条

[1] Simultaneous Targeting of CD19 and CD22: Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study
Amrolia, Persis J.
Wynn, Robert
Hough, Rachael
Vora, Ajay
Bonney, Denise
Veys, Paul
Rao, Kanchan
Chiesa, Robert
Al-Hajj, Muhammad
Cordoba, Shaun P.
Onuoha, Shimobi
Kotsopoulou, Ekaterini
Khokhar, Nushmia Z.
Pule, Martin
Peddareddigari, Vijay G. R.
[J]. BLOOD, 2018, 132
[2] [Anonymous], 2018, BLOOD, DOI [DOI 10.1182/BLOOD-2018-99-113126, DOI 10.1182/BLOOD-2018-99-116942]
[3] [Anonymous], 2018, BLOOD S1, DOI [DOI 10.1182/blood-2018-99-110142, DOI 10.1182/BLOOD-2018-99-110142]
[4] Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review
Anwer, Faiz
Shaukat, Al-Aman
Zahid, Umar
Husnain, Muhammad
McBride, Ali
Persky, Daniel
Lim, Melissa
Hasan, Nida
Bin Riaz, Irbaz
[J]. IMMUNOTHERAPY, 2017, 9 (02) : 123 - 130
[5] CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Brentjens, Renier J.
Davila, Marco L.
Riviere, Isabelle
Park, Jae
Wang, Xiuyan
Cowell, Lindsay G.
Bartido, Shirley
Stefanski, Jolanta
Taylor, Clare
Olszewska, Malgorzata
Borquez-Ojeda, Oriana
Qu, Jinrong
Wasielewska, Teresa
He, Qing
Bernal, Yvette
Rijo, Ivelise V.
Hedvat, Cyrus
Kobos, Rachel
Curran, Kevin
Steinherz, Peter
Jurcic, Joseph
Rosenblat, Todd
Maslak, Peter
Frattini, Mark
Sadelain, Michel
[J]. SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (177)
[6] Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
Brudno, Jennifer N.
Somerville, Robert P. T.
Shi, Victoria
Rose, Jeremy J.
Halverson, David C.
Fowler, Daniel H.
Gea-Banacloche, Juan C.
Pavletic, Steven Z.
Hickstein, Dennis D.
Lu, Tangying L.
Feldman, Steven A.
Iwamoto, Alexander T.
Kurlander, Roger
Maric, Irina
Goy, Andre
Hansen, Brenna G.
Wilder, Jennifer S.
Blacklock-Schuver, Bazetta
Hakim, Frances T.
Rosenberg, Steven A.
Gress, Ronald E.
Kochenderfer, James N.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) : 1112 - +
[7] Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation
Chen, Yuhong
Cheng, Yifei
Suo, Pan
Yan, Chenhua
Wang, Yu
Chen, Yao
Han, Wei
Xu, Lanping
Zhang, Xiaohui
Liu, Kaiyan
Chang, Lungji
Xiao, Lei
Huang, Xiaojun
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2017, 179 (04) : 598 - 605
[8] Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia
Dai, Hanren
Zhang, Wenying
Li, Xiaolei
Han, Qingwang
Guo, Yelei
Zhang, Yajing
Wang, Yao
Wang, Chunmeng
Shi, Fengxia
Zhang, Yan
Chen, Meixia
Feng, Kaichao
Wang, Quanshun
Zhu, Hongli
Fu, Xiaobing
Li, Suxia
Han, Weidong
[J]. ONCOIMMUNOLOGY, 2015, 4 (11):
[9] CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Fry, Terry J.
Shah, Nirali N.
Orentas, Rimas J.
Stetler-Stevenson, Maryalice
Yuan, Constance M.
Ramakrishna, Sneha
Wolters, Pamela
Martin, Staci
Delbrook, Cindy
Yates, Bonnie
Shalabi, Haneen
Fountaine, Thomas J.
Shern, Jack F.
Majzner, Robbie G.
Stroncek, David F.
Sabatino, Marianna
Feng, Yang
Dimitrov, Dimiter S.
Zhang, Ling
Sang Nguyen
Qin, Haiying
Dropulic, Boro
Lee, Daniel W.
Mackall, Crystal L.
[J]. NATURE MEDICINE, 2018, 24 (01) : 20 - +
[10] Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Gardner, Rebecca A.
Finney, Olivia
Annesley, Colleen
Brakke, Hannah
Summers, Corinne
Leger, Kasey
Bleakley, Marie
Brown, Christopher
Mgebroff, Stephanie
Kelly-Spratt, Karen S.
Hoglund, Virginia
Lindgren, Catherine
Oron, Assaf P.
Li, Daniel
Riddell, Stanley R.
Park, Julie R.
Jensen, Michael C.
[J]. BLOOD, 2017, 129 (25) : 3322 - 3331

← 1 2 3 →